Open AccessSignificance of Uracil/Tegafur for Preventing Intravesical Recurrence of Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Author(s) -
Kiyoshi Harada,
Hideaki Miyake,
Tomoaki Taguchi,
Masato Fujisawa
Publication year - 2012
Publication title -
current urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.476
H-Index - 13
eISSN - 1661-7657
pISSN - 1661-7649
DOI - 10.1159/000338866
Subject(s) - medicine , tegafur , vascular endothelial growth factor , urology , adjuvant , gastroenterology , bladder cancer , angiogenesis , oncology , cancer , vegf receptors
The objective of this study was to assess the role of uracil/tegafur (UFT) and its metabolite γ-butyrolactone (GBL), a potent inhibitor of angiogenesis, in the prevention of intravesical recurrence in patients with non-muscle invasive urothelial carcinoma of the bladder (NMIUCB).